MEDOCHEMIE was established in 1976 in Cyprus by Dr. Andreas Pittas and is still driven by the same philosophy: "To provide every human being around the globe with quality and affordable drug treatment in a manner that supports sustainability".
We develop, license, manufacture, market, and distribute branded generic and super-generic pharmaceutical products as well as our own patented brands.
The journey has seen our active expansion into promising markets across the world – from our base in Europe, to the Middle East & Africa, through to the Far East. Outside our 20 core offices, we developed a network of trusted agents and partners allowing us to operate in 106 countries.
Today, Medochemie Ltd has thirteen manufacturing plants and facilities. Nine are in Cyprus, one in the Netherlands, and three in Vietnam. We have acquired and maintain 3,800 marketing authorization licenses for 630 different pharmaceutical products, classified in over 10 therapeutic categories. We operate in accordance with the strictest quality standards and in full compliance with European guidelines.
The driving force behind Medochemie is our 1,370 multinational, talented, quality-focused employees, who work in our manufacturing plants and offices worldwide.
Medochemie is a founding member of the European Generic Medicines Association (EGA).